The global kounis syndrome market is expected to garner a market value of US$ 9098.96 Million in 2023 and is expected to accumulate a market value of US$ 15,990 Million by registering a CAGR of 5.8% in the forecast period 2023 to 2033.
Growth of the kounis syndrome market can be attributed to the rise in prevalence of chronic diseases, such as coronary artery disease, ischemic heart disease, and vascular diseases, the growing geriatric population, the wide range of products offered by the market players leading the kounis syndrome market to grow in future. The market for kounis syndrome registered a CAGR of 4.1% in the historical period 2017 to 2022
Kounis syndrome is the recurrence of acute coronary syndrome which are associated with mast cell activation. It also refers to a group of diseases in which blood flow to the heart decreases. Conditions related to kounis syndrome include ST-elevation myocardial infarction (STEMI), non-ST elevation myocardial infarction (NSTEMI), and unstable angina. It is a type of coronary heart disease (CHD), which is responsible for one-third of total deaths in people older than 35. Some forms of CHD can be asymptomatic, but ACS is always symptomatic.
Kounis syndrome is a manifestation of coronary heart disease and usually a result of plaque disruption in coronary arteries (atherosclerosis). Cocaine abuse can also lead to vasospasm. A family history of early myocardial infarction (55 years of age) is also a high-risk factor. Antihypertensive drugs are anticipated to show lucrative growth over the forecast period owing to increasing incidences of high blood pressure, myocardial infarction, and stroke.
| Report Attribute | Details |
|---|---|
| Expected Market Value (2023) | US$ 9098.96 Million |
| Anticipated Forecast Value (2033) | US$ 15,990 Million |
| Projected Growth Rate (2023 to 2033) | 5.8% CAGR |
Don't pay for what you don't need
Customize your report by selecting specific countries or regions and save 30%!
According to market research and competitive intelligence provider Future Market Insights- the market for Kounis syndrome reflected a value of 4.1% during the historical period, 2017 to 2022.
The number of elderly people reporting respective cardiovascular diseases is high. Owing to this, it is anticipated that the ever-increasing geriatric population, which is expected to rise in future years worldwide mainly in the Middle East and Africa & Asia-Pacific region, creates an opportunity for market growth in the forecast period. In addition, the integration of technological advancements for manufacturing medication to treat kounis syndrome is expected to boost the growth of the market.
Thus, the market for Kounis syndrome is expected to register a CAGR of 5.8% in the forecast period 2023 to 2033.
Research and development of medication and treatment supporting market growth
The rise in the prevalence of chronic diseases, such as coronary artery disease, ischemic heart disease, and vascular diseases the key reason for the growth of the kounis syndrome market. As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence of chronic heart and vascular diseases would help in finding novel solutions, and developing the cardiology and vascular devices would aid in more collaborations and partnerships with market players in the US, Europe, and Asia Pacific region.
This signifies that the increase in research and development investment for the discovery and development of treatments for kounis syndrome boosts the market growth.
Wide range of products offered by market players boosting Kounis syndrome market growth
Strategic product launches and collaborations done by major companies in interventional cardiology and peripheral vascular devices have opened up an opportunity to expand their business in various regions.
This strategy is allowing the companies to strengthen their footprints in the market. Therefore, it is predicted that strategic initiative is the golden opportunity for the market players to accelerate their revenue growth in the market.
The surge in technological advancements for cardiovascular disease creates lucrative opportunities for Kounis syndrome market
As technology advances rapidly, it improves how one manages cardiovascular diseases. In addition, recent healthcare monitoring applications and gadgets have enhanced the connection between patients and healthcare providers to update treatment plans and improve health outcomes. Thus, this is expected to create a significant opportunity for the global kounis market in the forecast period.
Also, governments in emerging markets (China, Brazil, Russia, India, and South Africa) reform public healthcare and grant more accessible access to medicine. These two factors working in unison mean greater freedom for market developments and increased innovation in clinical research in emerging markets.
Principal Consultant
Expensive nature of treatment and cardiology devices hampering the overall market growth
The rise in the cost of therapeutic surgery and the lack of accessibility to disease management services and support in low-economic countries are the restraints and challenges for the growth of kounis syndrome market.
The increased intricacy and cost of the cardiology devices and robust investments would increase the costs. The increased cost would result in delayed treatment of the patients in hospitals and clinics and clearance of this product is very rigorous and time-consuming many of the products find it difficult to get approved due to not complying with the regulations which may hamper the market growth.
Research and development activities finding novel solutions for the treatment of kounis syndrome
The major factor driving the growth of the kounis syndrome market rises in the prevalence of chronic diseases along with the growing geriatric population, and the wide range of products offered by market players leading the kounis syndrome market to grow in the future.
As the companies are constantly engaged in research and developmental activities, the knowledge about the prevalence of chronic heart and vascular diseases would help in finding novel solutions, and developing the cardiology and vascular devices would aid in more collaborations and partnerships with market players in the US, Europe, and Asia Pacific region. This signifies that the increase in research and development investment for the discovery and development of treatments of kounis syndrome boosts the market growth. Thus, North America is expected to possess a 40% market share of kounis syndrome market in 2023.
Lifestyle changes increasing the risk of kounis syndrome in Asia Pacific
ESCAP suggests that Asia Pacific is aging faster than any other region in the world. This, in turn, increases the number of people suffering from ailments in the Asia Pacific region. Fast-paced and sedentary lifestyles in the Asia Pacific region in countries like India, China, and Japan are increasing the prevalence of kounis syndrome
Furthermore, an increase in smoking, hypertension, diabetes, hyperlipidemia, physical inactivity, family obesity, and poor nutritional practices are other key factors leading to the growth of kounis syndrome in the Asia Pacific region. Thus, Asia Pacific is expected to possess a 36% market share of kounis syndrome market in 2023.
Get the data you need at a Fraction of the cost
Personalize your report by choosing insights you need
and save 40%!
Favorable reimbursement policies make hospitals a viable option for treatment
On the basis of distribution channel, the kounsin syndrome market is segmented into Laboratories Hospitals & Clinics
The hospital segment is expected to hold the largest market share for kounis syndrome. This is owing to the availability of various treatments and diagnostics in hospitals. In addition, the presence of healthcare experts and cardiologists is playing a key role in the wide usage of hospitals for the treatment of kounis syndrome.
In addition, initiatives by government authorities to support the treatment of kounis syndrome, especially in hospitals are favoring the growth of the same. Moreover, reimbursement schemes and their benefits are making hospitals a go-to option for the treatment of kounis syndrome. Thus, hospitals and clinics are expected to hold a 55% market share of kounis syndrome market in 2023.
Key start-up players in the kounis syndrome market are CardioDX, Verily, CVRX, BlueRock Therapeutics, CARMAT, and Cleerly
Key players in the kounis syndrome market are Jordan Hospital & Medical Center, Fortis Hospital Anandapur, Samsung Medical Center, Hospital Mae de Deus, Premier Medica, National Taiwan University Hospital, Muro General Hospital, Herzinstitut Berlin, Kyung Hee University Hospital, HELIOS Dr. Horst Schmidt Hospital Wiesbaden
| Report Attribute | Details |
|---|---|
| Market Value in 2023 | US$ 9098.96 Million |
| Market Value in 2033 | US$ 15,990 Million |
| Growth Rate | CAGR of 5.8% from 2023 to 2033 |
| Base Year for Estimation | 2022 |
| Historical Data | 2017 to 2022 |
| Forecast Period | 2023 to 2033 |
| Quantitative Units | Revenue in USD Million and CAGR from 2023 to 2033 |
| Report Coverage | Revenue Forecast, Volume Forecast, Company Ranking, Competitive Landscape, Growth Factors, Trends, and Pricing Analysis |
| Segments Covered | Treatment Procedure, Distribution Channel, Region |
| Regions Covered | North America; Latin America; South Asia; East Asia; Oceania; Middle East & Africa (MEA) |
| Key Countries Profiled | The USA, Canada, Brazil, Argentina, Germany, The UK, France, Spain, Italy, Nordics, BENELUX, Australia & New Zealand, China, India, Association of Southeast Asian Nations, GCC, South Africa |
| Key Companies Profiled | Jordan Hospital & Medical Center; Fortis Hospital Anandapur; Samsung Medical Center; Hospital Mae de Deus; Premier Medica; National Taiwan University Hospital; Muro General Hospital; Herzinstitut Berlin; Kyung Hee University Hospital; HELIOS Dr. Horst Schmidt Hospital Wiesbaden |
| Customization | Available Upon Request |
From 2017 to 2022, the Kounis syndrome market grew at a CAGR of 4.1%
The global Kounis syndrome market is expected to grow with a 5.8% CAGR from 2023 to 2033.
As of 2033, the Kounis syndrome market is expected to reach US$ 15,990 Million
The hospitals and clinics segment is expected to hold 55% of the market share in 2023 for the Kounis syndrome market.
North America is expected to possess a 40% market share for the Kounis syndrome market in 2023.
Asia Pacific Kounis syndrome market size is expected to possess a 36% market share in 2023.
1. Executive Summary | Kounis Syndrome Market 1.1. Global Market Outlook 1.2. Demand-side Trends 1.3. Supply-side Trends 1.4. Technology Roadmap Analysis 1.5. Analysis and Recommendations 2. Market Overview 2.1. Market Coverage / Taxonomy 2.2. Market Definition / Scope / Limitations 3. Market Background 3.1. Market Dynamics 3.1.1. Drivers 3.1.2. Restraints 3.1.3. Opportunity 3.1.4. Trends 3.2. Scenario Forecast 3.2.1. Demand in Optimistic Scenario 3.2.2. Demand in Likely Scenario 3.2.3. Demand in Conservative Scenario 3.3. Opportunity Map Analysis 3.4. Investment Feasibility Matrix 3.5. PESTLE and Porter’s Analysis 3.6. Regulatory Landscape 3.6.1. By Key Regions 3.6.2. By Key Countries 3.7. Regional Parent Market Outlook 4. GlobalMarket Analysis 2018 to 2022 and Forecast, 2023 to 2033 4.1. Historical Market Size Value (US$ Million) Analysis, 2018 to 2022 4.2. Current and Future Market Size Value (US$ Million) Projections, 2023 to 2033 4.2.1. Y-o-Y Growth Trend Analysis 4.2.2. Absolute $ Opportunity Analysis 5. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Treatment Procedure 5.1. Introduction / Key Findings 5.2. Historical Market Size Value (US$ Million) Analysis By Treatment Procedure, 2018 to 2022 5.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Treatment Procedure, 2023 to 2033 5.3.1. Tests 5.3.1.1. Blood tests 5.3.1.2. Chest x-ray 5.3.1.3. ECG 5.3.1.4. EKG 5.3.1.5. MRI 5.3.1.6. Angiography 5.3.2. Treatment 5.3.2.1. Beta-lactam antibiotics 5.3.2.2. Non-steroidal anti-inflammatory drugs 5.3.2.3. Rocuronium 5.3.2.4. Others 5.4. Y-o-Y Growth Trend Analysis By Treatment Procedure, 2018 to 2022 5.5. Absolute $ Opportunity Analysis By Treatment Procedure, 2023 to 2033 6. Global Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Distribution Channel 6.1. Introduction / Key Findings 6.2. Historical Market Size Value (US$ Million) Analysis By Distribution Channel, 2018 to 2022 6.3. Current and Future Market Size Value (US$ Million) Analysis and Forecast By Distribution Channel, 2023 to 2033 6.3.1. Laboratories 6.3.2. Hospitals & Clinics 6.4. Y-o-Y Growth Trend Analysis By Distribution Channel, 2018 to 2022 6.5. Absolute $ Opportunity Analysis By Distribution Channel, 2023 to 2033 7. GlobalMarket Analysis 2018 to 2022 and Forecast 2023 to 2033, By Region 7.1. Introduction 7.2. Historical Market Size Value (US$ Million) Analysis By Region, 2018 to 2022 7.3. Current Market Size Value (US$ Million) Analysis and Forecast By Region, 2023 to 2033 7.3.1. North America 7.3.2. Latin America 7.3.3. Europe 7.3.4. South Asia 7.3.5. East Asia 7.3.6. Oceania 7.3.7. Middle East & Africa (MEA) 7.4. Market Attractiveness Analysis By Region 8. North America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 8.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 8.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 8.2.1. By Country 8.2.1.1. The US 8.2.1.2. Canada 8.2.2. By Treatment Procedure 8.2.3. By Distribution Channel 8.3. Market Attractiveness Analysis 8.3.1. By Country 8.3.2. By Treatment Procedure 8.3.3. By Distribution Channel 8.4. Key Takeaways 9. Latin America Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 9.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 9.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 9.2.1. By Country 9.2.1.1. Brazil 9.2.1.2. Mexico 9.2.1.3. Rest of Latin America 9.2.2. By Treatment Procedure 9.2.3. By Distribution Channel 9.3. Market Attractiveness Analysis 9.3.1. By Country 9.3.2. By Treatment Procedure 9.3.3. By Distribution Channel 9.4. Key Takeaways 10. Europe Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 10.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 10.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 10.2.1. By Country 10.2.1.1. Germany 10.2.1.2. The UK 10.2.1.3. France 10.2.1.4. Spain 10.2.1.5. Italy 10.2.1.6. Rest of Europe 10.2.2. By Treatment Procedure 10.2.3. By Distribution Channel 10.3. Market Attractiveness Analysis 10.3.1. By Country 10.3.2. By Treatment Procedure 10.3.3. By Distribution Channel 10.4. Key Takeaways 11. South Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 11.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 11.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 11.2.1. By Country 11.2.1.1. India 11.2.1.2. Malaysia 11.2.1.3. Singapore 11.2.1.4. Thailand 11.2.1.5. Rest of South Asia 11.2.2. By Treatment Procedure 11.2.3. By Distribution Channel 11.3. Market Attractiveness Analysis 11.3.1. By Country 11.3.2. By Treatment Procedure 11.3.3. By Distribution Channel 11.4. Key Takeaways 12. East Asia Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 12.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 12.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 12.2.1. By Country 12.2.1.1. China 12.2.1.2. Japan 12.2.1.3. South Korea 12.2.2. By Treatment Procedure 12.2.3. By Distribution Channel 12.3. Market Attractiveness Analysis 12.3.1. By Country 12.3.2. By Treatment Procedure 12.3.3. By Distribution Channel 12.4. Key Takeaways 13. Oceania Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 13.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 13.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 13.2.1. By Country 13.2.1.1. Australia 13.2.1.2. New Zealand 13.2.2. By Treatment Procedure 13.2.3. By Distribution Channel 13.3. Market Attractiveness Analysis 13.3.1. By Country 13.3.2. By Treatment Procedure 13.3.3. By Distribution Channel 13.4. Key Takeaways 14. MEA Market Analysis 2018 to 2022 and Forecast 2023 to 2033, By Country 14.1. Historical Market Size Value (US$ Million) Trend Analysis By Market Taxonomy, 2018 to 2022 14.2. Market Size Value (US$ Million) Forecast By Market Taxonomy, 2023 to 2033 14.2.1. By Country 14.2.1.1. GCC Countries 14.2.1.2. South Africa 14.2.1.3. Israel 14.2.1.4. Rest of MEA 14.2.2. By Treatment Procedure 14.2.3. By Distribution Channel 14.3. Market Attractiveness Analysis 14.3.1. By Country 14.3.2. By Treatment Procedure 14.3.3. By Distribution Channel 14.4. Key Takeaways 15. Key Countries Market Analysis 15.1. The US 15.1.1. Pricing Analysis 15.1.2. Market Share Analysis, 2022 15.1.2.1. By Treatment Procedure 15.1.2.2. By Distribution Channel 15.2. Canada 15.2.1. Pricing Analysis 15.2.2. Market Share Analysis, 2022 15.2.2.1. By Treatment Procedure 15.2.2.2. By Distribution Channel 15.3. Brazil 15.3.1. Pricing Analysis 15.3.2. Market Share Analysis, 2022 15.3.2.1. By Treatment Procedure 15.3.2.2. By Distribution Channel 15.4. Mexico 15.4.1. Pricing Analysis 15.4.2. Market Share Analysis, 2022 15.4.2.1. By Treatment Procedure 15.4.2.2. By Distribution Channel 15.5. Germany 15.5.1. Pricing Analysis 15.5.2. Market Share Analysis, 2022 15.5.2.1. By Treatment Procedure 15.5.2.2. By Distribution Channel 15.6. The UK 15.6.1. Pricing Analysis 15.6.2. Market Share Analysis, 2022 15.6.2.1. By Treatment Procedure 15.6.2.2. By Distribution Channel 15.7. France 15.7.1. Pricing Analysis 15.7.2. Market Share Analysis, 2022 15.7.2.1. By Treatment Procedure 15.7.2.2. By Distribution Channel 15.8. Spain 15.8.1. Pricing Analysis 15.8.2. Market Share Analysis, 2022 15.8.2.1. By Treatment Procedure 15.8.2.2. By Distribution Channel 15.9. Italy 15.9.1. Pricing Analysis 15.9.2. Market Share Analysis, 2022 15.9.2.1. By Treatment Procedure 15.9.2.2. By Distribution Channel 15.10. India 15.10.1. Pricing Analysis 15.10.2. Market Share Analysis, 2022 15.10.2.1. By Treatment Procedure 15.10.2.2. By Distribution Channel 15.11. Malaysia 15.11.1. Pricing Analysis 15.11.2. Market Share Analysis, 2022 15.11.2.1. By Treatment Procedure 15.11.2.2. By Distribution Channel 15.12. Singapore 15.12.1. Pricing Analysis 15.12.2. Market Share Analysis, 2022 15.12.2.1. By Treatment Procedure 15.12.2.2. By Distribution Channel 15.13. Thailand 15.13.1. Pricing Analysis 15.13.2. Market Share Analysis, 2022 15.13.2.1. By Treatment Procedure 15.13.2.2. By Distribution Channel 15.14. China 15.14.1. Pricing Analysis 15.14.2. Market Share Analysis, 2022 15.14.2.1. By Treatment Procedure 15.14.2.2. By Distribution Channel 15.15. Japan 15.15.1. Pricing Analysis 15.15.2. Market Share Analysis, 2022 15.15.2.1. By Treatment Procedure 15.15.2.2. By Distribution Channel 15.16. South Korea 15.16.1. Pricing Analysis 15.16.2. Market Share Analysis, 2022 15.16.2.1. By Treatment Procedure 15.16.2.2. By Distribution Channel 15.17. Australia 15.17.1. Pricing Analysis 15.17.2. Market Share Analysis, 2022 15.17.2.1. By Treatment Procedure 15.17.2.2. By Distribution Channel 15.18. New Zealand 15.18.1. Pricing Analysis 15.18.2. Market Share Analysis, 2022 15.18.2.1. By Treatment Procedure 15.18.2.2. By Distribution Channel 15.19. GCC Countries 15.19.1. Pricing Analysis 15.19.2. Market Share Analysis, 2022 15.19.2.1. By Treatment Procedure 15.19.2.2. By Distribution Channel 15.20. South Africa 15.20.1. Pricing Analysis 15.20.2. Market Share Analysis, 2022 15.20.2.1. By Treatment Procedure 15.20.2.2. By Distribution Channel 15.21. Israel 15.21.1. Pricing Analysis 15.21.2. Market Share Analysis, 2022 15.21.2.1. By Treatment Procedure 15.21.2.2. By Distribution Channel 16. Market Structure Analysis 16.1. Competition Dashboard 16.2. Competition Benchmarking 16.3. Market Share Analysis of Top Players 16.3.1. By Regional 16.3.2. By Treatment Procedure 16.3.3. By Distribution Channel 17. Competition Analysis 17.1. Competition Deep Dive 17.1.1. Jordan Hospital & Medical Center 17.1.1.1. Overview 17.1.1.2. Product Portfolio 17.1.1.3. Profitability by Market Segments 17.1.1.4. Sales Footprint 17.1.1.5. Strategy Overview 17.1.1.5.1. Marketing Strategy 17.1.2. Fortis Hospital Anandapur 17.1.2.1. Overview 17.1.2.2. Product Portfolio 17.1.2.3. Profitability by Market Segments 17.1.2.4. Sales Footprint 17.1.2.5. Strategy Overview 17.1.2.5.1. Marketing Strategy 17.1.3. Samsung Medical Center 17.1.3.1. Overview 17.1.3.2. Product Portfolio 17.1.3.3. Profitability by Market Segments 17.1.3.4. Sales Footprint 17.1.3.5. Strategy Overview 17.1.3.5.1. Marketing Strategy 17.1.4. Hospital Mae de Deus 17.1.4.1. Overview 17.1.4.2. Product Portfolio 17.1.4.3. Profitability by Market Segments 17.1.4.4. Sales Footprint 17.1.4.5. Strategy Overview 17.1.4.5.1. Marketing Strategy 17.1.5. Premier Medica 17.1.5.1. Overview 17.1.5.2. Product Portfolio 17.1.5.3. Profitability by Market Segments 17.1.5.4. Sales Footprint 17.1.5.5. Strategy Overview 17.1.5.5.1. Marketing Strategy 17.1.6. National Taiwan University Hospital 17.1.6.1. Overview 17.1.6.2. Product Portfolio 17.1.6.3. Profitability by Market Segments 17.1.6.4. Sales Footprint 17.1.6.5. Strategy Overview 17.1.6.5.1. Marketing Strategy 17.1.7. Muro General Hospital 17.1.7.1. Overview 17.1.7.2. Product Portfolio 17.1.7.3. Profitability by Market Segments 17.1.7.4. Sales Footprint 17.1.7.5. Strategy Overview 17.1.7.5.1. Marketing Strategy 17.1.8. Herzinstitut Berlin 17.1.8.1. Overview 17.1.8.2. Product Portfolio 17.1.8.3. Profitability by Market Segments 17.1.8.4. Sales Footprint 17.1.8.5. Strategy Overview 17.1.8.5.1. Marketing Strategy 17.1.9. Kyung Hee University Hospital 17.1.9.1. Overview 17.1.9.2. Product Portfolio 17.1.9.3. Profitability by Market Segments 17.1.9.4. Sales Footprint 17.1.9.5. Strategy Overview 17.1.9.5.1. Marketing Strategy 17.1.10. HELIOS Dr. Horst Schmidt Hospital Wiesbaden 17.1.10.1. Overview 17.1.10.2. Product Portfolio 17.1.10.3. Profitability by Market Segments 17.1.10.4. Sales Footprint 17.1.10.5. Strategy Overview 17.1.10.5.1. Marketing Strategy 18. Assumptions & Acronyms Used 19. Research Methodology
Explore Healthcare Insights
View Reports
Kounis Syndrome Market
